http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 27 May 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html <p align="justify">LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences.</p> <p><strong>William Blair’s 46th Annual Growth Stock Conference</strong><br />Date and time: June 2, 2026; 1:20pm CDT / 7:20pm BST<br />Location: Chicago, IL<br />Presenter: Chief Executive Officer Dr. Christian Itin</p> <p align="justify"><strong>Jefferies Global Healthcare Conference</strong><br />Date and time: June 3, 2026; 10:30am EDT / 3:30pm BST<br />Location: New York, NY<br />Presenter: Chief Executive Officer Dr. Christian http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html Wed, 27 May 2026 07:00:00 -0400 AUTL AUTL http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html <p align="justify">LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences.</p> <p><strong>William Blair’s 46th Annual Growth Stock Conference</strong><br />Date and time: June 2, 2026; 1:20pm CDT / 7:20pm BST<br />Location: Chicago, IL<br />Presenter: Chief Executive Officer Dr. Christian Itin</p> <p align="justify"><strong>Jefferies Global Healthcare Conference</strong><br />Date and time: June 3, 2026; 10:30am EDT / 3:30pm BST<br />Location: New York, NY<br />Presenter: Chief Executive Officer Dr. Christian http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html Wed, 27 May 2026 07:00:00 -0400 AUTL AUTL http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html <p align="justify">LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences.</p> <p><strong>William Blair’s 46th Annual Growth Stock Conference</strong><br />Date and time: June 2, 2026; 1:20pm CDT / 7:20pm BST<br />Location: Chicago, IL<br />Presenter: Chief Executive Officer Dr. Christian Itin</p> <p align="justify"><strong>Jefferies Global Healthcare Conference</strong><br />Date and time: June 3, 2026; 10:30am EDT / 3:30pm BST<br />Location: New York, NY<br />Presenter: Chief Executive Officer Dr. Christian http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html Wed, 27 May 2026 07:00:00 -0400 AUTL AUTL http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html <p align="justify">LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences.</p> <p><strong>William Blair’s 46th Annual Growth Stock Conference</strong><br />Date and time: June 2, 2026; 1:20pm CDT / 7:20pm BST<br />Location: Chicago, IL<br />Presenter: Chief Executive Officer Dr. Christian Itin</p> <p align="justify"><strong>Jefferies Global Healthcare Conference</strong><br />Date and time: June 3, 2026; 10:30am EDT / 3:30pm BST<br />Location: New York, NY<br />Presenter: Chief Executive Officer Dr. Christian http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Participate+in+Upcoming+Investor+Conferences/26553237.html Wed, 27 May 2026 07:00:00 -0400 AUTL AUTL http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Press+Releases/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html <p align="justify">LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p> <p align="justify">“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival http://www.streetinsider.com/Globe+Newswire/Autolus+Therapeutics+to+Present+Clinical+Data+Update+at+the+American+Society+of+Clinical+Oncology+Annual+Meeting+2026/26536774.html Thu, 21 May 2026 17:10:00 -0400 A.31293549 A.32727947 A.50216726 AUTL O.00048394 O.00573636 O.21612337 O.37399203 http://www.streetinsider.com/Press+Releases/Immunic+Appoints+Seasoned+Biopharmaceutical+Executive+Michael+W.+Bonney+as+Chair+of+the+Board+of+Directors/26516800.html <div class="xn-content"> <p class="prntac"><i>– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization –</i></p><p class="prntac"><i>– Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis –</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>May 19, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4690939-1&amp;h=2682646987&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc." target="_blank" rel="nofollow"><b><span value="NASDAQ-NMS:IMUX" idsrc="xmltag.org" >Immunic, Inc.</span></b></a><b> (Nasdaq: IMUX)</b>, a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" <person>W. Bonney</person>, a highly experienced biopharmaceutical executive and board leader, as Chair of its Board of Directors, effective <chron>May 16, 2026</chron>. <person>Simona Skerjanec</person>, <person>M.Pharm</person>, MBA, will transition from Interim http://www.streetinsider.com/Press+Releases/Immunic+Appoints+Seasoned+Biopharmaceutical+Executive+Michael+W.+Bonney+as+Chair+of+the+Board+of+Directors/26516800.html Tue, 19 May 2026 06:30:00 -0400 A.08291962 A.13662202 A.29582908 A.50215005 AUTL IMUX O.00063751 O.00085455 O.02321652 O.28898064 O.37399203 O.47086594 http://www.streetinsider.com/Press+Releases/Immunic+Appoints+Seasoned+Biopharmaceutical+Executive+Michael+W.+Bonney+as+Chair+of+the+Board+of+Directors/26516800.html <div class="xn-content"> <p class="prntac"><i>– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization –</i></p><p class="prntac"><i>– Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis –</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>May 19, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4690939-1&amp;h=2682646987&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc." target="_blank" rel="nofollow"><b><span value="NASDAQ-NMS:IMUX" idsrc="xmltag.org" >Immunic, Inc.</span></b></a><b> (Nasdaq: IMUX)</b>, a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" <person>W. Bonney</person>, a highly experienced biopharmaceutical executive and board leader, as Chair of its Board of Directors, effective <chron>May 16, 2026</chron>. <person>Simona Skerjanec</person>, <person>M.Pharm</person>, MBA, will transition from Interim http://www.streetinsider.com/Press+Releases/Immunic+Appoints+Seasoned+Biopharmaceutical+Executive+Michael+W.+Bonney+as+Chair+of+the+Board+of+Directors/26516800.html Tue, 19 May 2026 06:30:00 -0400 A.08291962 A.13662202 A.29582908 A.50215005 AUTL IMUX O.00063751 O.00085455 O.02321652 O.28898064 O.37399203 O.47086594 http://www.streetinsider.com/Press+Releases/Immunic+Appoints+Seasoned+Biopharmaceutical+Executive+Michael+W.+Bonney+as+Chair+of+the+Board+of+Directors/26516800.html <div class="xn-content"> <p class="prntac"><i>– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization –</i></p><p class="prntac"><i>– Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis –</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>May 19, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4690939-1&amp;h=2682646987&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc." target="_blank" rel="nofollow"><b><span value="NASDAQ-NMS:IMUX" idsrc="xmltag.org" >Immunic, Inc.</span></b></a><b> (Nasdaq: IMUX)</b>, a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" <person>W. Bonney</person>, a highly experienced biopharmaceutical executive and board leader, as Chair of its Board of Directors, effective <chron>May 16, 2026</chron>. <person>Simona Skerjanec</person>, <person>M.Pharm</person>, MBA, will transition from Interim http://www.streetinsider.com/Press+Releases/Immunic+Appoints+Seasoned+Biopharmaceutical+Executive+Michael+W.+Bonney+as+Chair+of+the+Board+of+Directors/26516800.html Tue, 19 May 2026 06:30:00 -0400 A.08291962 A.13662202 A.29582908 A.50215005 AUTL IMUX O.00063751 O.00085455 O.02321652 O.28898064 O.37399203 O.47086594 http://www.streetinsider.com/Press+Releases/Immunic+Appoints+Seasoned+Biopharmaceutical+Executive+Michael+W.+Bonney+as+Chair+of+the+Board+of+Directors/26516800.html <div class="xn-content"> <p class="prntac"><i>– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization –</i></p><p class="prntac"><i>– Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis –</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>May 19, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4690939-1&amp;h=2682646987&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc." target="_blank" rel="nofollow"><b><span value="NASDAQ-NMS:IMUX" idsrc="xmltag.org" >Immunic, Inc.</span></b></a><b> (Nasdaq: IMUX)</b>, a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" <person>W. Bonney</person>, a highly experienced biopharmaceutical executive and board leader, as Chair of its Board of Directors, effective <chron>May 16, 2026</chron>. <person>Simona Skerjanec</person>, <person>M.Pharm</person>, MBA, will transition from Interim http://www.streetinsider.com/Press+Releases/Immunic+Appoints+Seasoned+Biopharmaceutical+Executive+Michael+W.+Bonney+as+Chair+of+the+Board+of+Directors/26516800.html Tue, 19 May 2026 06:30:00 -0400 A.08291962 A.13662202 A.29582908 A.50215005 AUTL IMUX O.00063751 O.00085455 O.02321652 O.28898064 O.37399203 O.47086594 http://www.streetinsider.com/Press+Releases/Immunic+Appoints+Seasoned+Biopharmaceutical+Executive+Michael+W.+Bonney+as+Chair+of+the+Board+of+Directors/26516800.html <div class="xn-content"> <p class="prntac"><i>– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization –</i></p><p class="prntac"><i>– Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis –</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>May 19, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4690939-1&amp;h=2682646987&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc." target="_blank" rel="nofollow"><b><span value="NASDAQ-NMS:IMUX" idsrc="xmltag.org" >Immunic, Inc.</span></b></a><b> (Nasdaq: IMUX)</b>, a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" <person>W. Bonney</person>, a highly experienced biopharmaceutical executive and board leader, as Chair of its Board of Directors, effective <chron>May 16, 2026</chron>. <person>Simona Skerjanec</person>, <person>M.Pharm</person>, MBA, will transition from Interim http://www.streetinsider.com/Press+Releases/Immunic+Appoints+Seasoned+Biopharmaceutical+Executive+Michael+W.+Bonney+as+Chair+of+the+Board+of+Directors/26516800.html Tue, 19 May 2026 06:30:00 -0400 A.08291962 A.13662202 A.29582908 A.50215005 AUTL IMUX O.00063751 O.00085455 O.02321652 O.28898064 O.37399203 O.47086594